nodes	percent_of_prediction	percent_of_DWPC	metapath
Lithium—GSK3B—schizophrenia	0.739	1	CbGaD
Lithium—IMPA1—forebrain—schizophrenia	0.00437	0.0535	CbGeAlD
Lithium—IMPA1—telencephalon—schizophrenia	0.00401	0.0492	CbGeAlD
Lithium—GRIA3—forebrain—schizophrenia	0.00371	0.0455	CbGeAlD
Lithium—GRIA3—telencephalon—schizophrenia	0.00341	0.0418	CbGeAlD
Lithium—IMPA1—gonad—schizophrenia	0.00335	0.0411	CbGeAlD
Lithium—GSK3B—forebrain—schizophrenia	0.00321	0.0394	CbGeAlD
Lithium—GSK3B—telencephalon—schizophrenia	0.00296	0.0362	CbGeAlD
Lithium—IMPA1—blood—schizophrenia	0.00292	0.0358	CbGeAlD
Lithium—GSK3A—forebrain—schizophrenia	0.00279	0.0343	CbGeAlD
Lithium—GSK3A—telencephalon—schizophrenia	0.00257	0.0315	CbGeAlD
Lithium—IMPA1—endocrine gland—schizophrenia	0.00253	0.031	CbGeAlD
Lithium—GSK3B—gonad—schizophrenia	0.00247	0.0302	CbGeAlD
Lithium—GRIA3—midbrain—schizophrenia	0.00245	0.03	CbGeAlD
Lithium—IMPA1—nervous system—schizophrenia	0.00237	0.029	CbGeAlD
Lithium—IMPA1—central nervous system—schizophrenia	0.00228	0.028	CbGeAlD
Lithium—IMPA2—blood—schizophrenia	0.00219	0.0268	CbGeAlD
Lithium—GSK3B—blood—schizophrenia	0.00215	0.0263	CbGeAlD
Lithium—GSK3A—gonad—schizophrenia	0.00214	0.0263	CbGeAlD
Lithium—GRIA3—nervous system—schizophrenia	0.00201	0.0247	CbGeAlD
Lithium—GRIA3—central nervous system—schizophrenia	0.00194	0.0238	CbGeAlD
Lithium—GRIA3—cerebellum—schizophrenia	0.0019	0.0232	CbGeAlD
Lithium—GSK3A—blood—schizophrenia	0.00187	0.0229	CbGeAlD
Lithium—GSK3B—endocrine gland—schizophrenia	0.00186	0.0228	CbGeAlD
Lithium—GSK3A—midbrain—schizophrenia	0.00185	0.0226	CbGeAlD
Lithium—IMPA1—brain—schizophrenia	0.00181	0.0222	CbGeAlD
Lithium—GSK3B—nervous system—schizophrenia	0.00174	0.0214	CbGeAlD
Lithium—GSK3B—central nervous system—schizophrenia	0.00168	0.0206	CbGeAlD
Lithium—GSK3B—cerebellum—schizophrenia	0.00164	0.0201	CbGeAlD
Lithium—GSK3A—endocrine gland—schizophrenia	0.00162	0.0199	CbGeAlD
Lithium—GRIA3—brain—schizophrenia	0.00154	0.0189	CbGeAlD
Lithium—GSK3A—nervous system—schizophrenia	0.00152	0.0186	CbGeAlD
Lithium—GSK3A—central nervous system—schizophrenia	0.00146	0.0179	CbGeAlD
Lithium—GSK3A—cerebellum—schizophrenia	0.00143	0.0175	CbGeAlD
Lithium—IMPA2—brain—schizophrenia	0.00136	0.0167	CbGeAlD
Lithium—GSK3B—brain—schizophrenia	0.00133	0.0163	CbGeAlD
Lithium—GSK3A—brain—schizophrenia	0.00116	0.0142	CbGeAlD
Lithium—GSK3A—Innate Immune System—ERBB3—schizophrenia	3.55e-05	0.000198	CbGpPWpGaD
Lithium—GSK3B—Immune System—IL3RA—schizophrenia	3.53e-05	0.000196	CbGpPWpGaD
Lithium—GSK3B—Corticotropin-releasing hormone—AKT1—schizophrenia	3.52e-05	0.000195	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—YWHAZ—schizophrenia	3.49e-05	0.000194	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MAG—schizophrenia	3.47e-05	0.000193	CbGpPWpGaD
Lithium—GSK3B—Immune System—NRG3—schizophrenia	3.45e-05	0.000192	CbGpPWpGaD
Lithium—GSK3A—Disease—FGA—schizophrenia	3.43e-05	0.000191	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—ERBB3—schizophrenia	3.41e-05	0.00019	CbGpPWpGaD
Lithium—GSK3A—Signaling by SCF-KIT—AKT1—schizophrenia	3.38e-05	0.000188	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—FZD3—schizophrenia	3.38e-05	0.000188	CbGpPWpGaD
Lithium—GSK3B—B Cell Receptor Signaling Pathway—AKT1—schizophrenia	3.37e-05	0.000187	CbGpPWpGaD
Lithium—GSK3B—PI-3K cascade—AKT1—schizophrenia	3.34e-05	0.000186	CbGpPWpGaD
Lithium—GSK3B—PI3K/AKT activation—AKT1—schizophrenia	3.26e-05	0.000181	CbGpPWpGaD
Lithium—GSK3B—GAB1 signalosome—AKT1—schizophrenia	3.24e-05	0.00018	CbGpPWpGaD
Lithium—GSK3A—Downstream signaling of activated FGFR—AKT1—schizophrenia	3.23e-05	0.00018	CbGpPWpGaD
Lithium—GSK3A—Integrated Breast Cancer Pathway—AKT1—schizophrenia	3.2e-05	0.000178	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB4—AKT1—schizophrenia	3.18e-05	0.000177	CbGpPWpGaD
Lithium—GSK3B—Disease—TLE1—schizophrenia	3.18e-05	0.000177	CbGpPWpGaD
Lithium—GSK3B—Disease—NRG3—schizophrenia	3.18e-05	0.000177	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TAAR6—schizophrenia	3.18e-05	0.000177	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PPP3CC—schizophrenia	3.18e-05	0.000177	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—FES—schizophrenia	3.18e-05	0.000177	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—GRM2—schizophrenia	3.18e-05	0.000177	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—S100B—schizophrenia	3.18e-05	0.000177	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CHRM1—schizophrenia	3.17e-05	0.000176	CbGpPWpGaD
Lithium—GSK3B—Role of LAT2/NTAL/LAB on calcium mobilization—AKT1—schizophrenia	3.16e-05	0.000176	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—MEF2C—schizophrenia	3.15e-05	0.000175	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—TP53—schizophrenia	3.14e-05	0.000175	CbGpPWpGaD
Lithium—GSK3B—Circadian rythm related genes—EP300—schizophrenia	3.11e-05	0.000173	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—IL3RA—schizophrenia	3.09e-05	0.000172	CbGpPWpGaD
Lithium—GSK3B—DNA Damage Response (only ATM dependent)—AKT1—schizophrenia	3.07e-05	0.000171	CbGpPWpGaD
Lithium—GSK3A—Insulin Signaling—AKT1—schizophrenia	3.06e-05	0.00017	CbGpPWpGaD
Lithium—GSK3A—Downstream signal transduction—AKT1—schizophrenia	3.04e-05	0.000169	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—ERBB4—schizophrenia	3.04e-05	0.000169	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR—AKT1—schizophrenia	3.03e-05	0.000168	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TLE1—schizophrenia	3.01e-05	0.000168	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—NRG3—schizophrenia	3.01e-05	0.000168	CbGpPWpGaD
Lithium—GSK3B—Disease—TLE3—schizophrenia	3.01e-05	0.000167	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB2—AKT1—schizophrenia	3.01e-05	0.000167	CbGpPWpGaD
Lithium—GSK3A—Immune System—HLA-E—schizophrenia	3e-05	0.000167	CbGpPWpGaD
Lithium—GSK3B—Immune System—CAMK2B—schizophrenia	3e-05	0.000167	CbGpPWpGaD
Lithium—GSK3A—Disease—SNAP25—schizophrenia	3e-05	0.000167	CbGpPWpGaD
Lithium—GSK3A—DAP12 signaling—AKT1—schizophrenia	3e-05	0.000167	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—GFAP—schizophrenia	2.98e-05	0.000166	CbGpPWpGaD
Lithium—GSK3A—Downstream signaling events of B Cell Receptor (BCR)—AKT1—schizophrenia	2.95e-05	0.000164	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—GRM5—schizophrenia	2.95e-05	0.000164	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NGEF—schizophrenia	2.94e-05	0.000163	CbGpPWpGaD
Lithium—GSK3B—TCF dependent signaling in response to WNT—EP300—schizophrenia	2.92e-05	0.000162	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—ERBB4—schizophrenia	2.92e-05	0.000162	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NTS—schizophrenia	2.87e-05	0.00016	CbGpPWpGaD
Lithium—GSK3B—Disease—GAPDH—schizophrenia	2.87e-05	0.00016	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TLE3—schizophrenia	2.85e-05	0.000159	CbGpPWpGaD
Lithium—GSK3B—RNF mutants show enhanced WNT signaling and proliferation—EP300—schizophrenia	2.82e-05	0.000157	CbGpPWpGaD
Lithium—GSK3A—DAP12 interactions—AKT1—schizophrenia	2.82e-05	0.000157	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR in disease—AKT1—schizophrenia	2.82e-05	0.000157	CbGpPWpGaD
Lithium—GSK3A—Fc epsilon receptor (FCERI) signaling—AKT1—schizophrenia	2.82e-05	0.000157	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—NRG1—schizophrenia	2.8e-05	0.000156	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR—AKT1—schizophrenia	2.79e-05	0.000155	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—MEF2C—schizophrenia	2.78e-05	0.000154	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR in Cancer—AKT1—schizophrenia	2.77e-05	0.000154	CbGpPWpGaD
Lithium—GSK3A—Signaling by PDGF—AKT1—schizophrenia	2.76e-05	0.000153	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—GSK3B—schizophrenia	2.75e-05	0.000153	CbGpPWpGaD
Lithium—GSK3B—Immune System—NCAM1—schizophrenia	2.75e-05	0.000153	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—FOS—schizophrenia	2.74e-05	0.000152	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—GRM3—schizophrenia	2.7e-05	0.00015	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—RGS4—schizophrenia	2.7e-05	0.00015	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—RTN4—schizophrenia	2.7e-05	0.00015	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CCK—schizophrenia	2.7e-05	0.00015	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—NRG1—schizophrenia	2.69e-05	0.00015	CbGpPWpGaD
Lithium—GSK3A—Disease—HSPA1A—schizophrenia	2.69e-05	0.00015	CbGpPWpGaD
Lithium—GSK3A—Immune System—PRL—schizophrenia	2.69e-05	0.000149	CbGpPWpGaD
Lithium—GSK3A—Disease—NOS1—schizophrenia	2.67e-05	0.000149	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—AKT1—schizophrenia	2.65e-05	0.000147	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—HTR6—schizophrenia	2.65e-05	0.000147	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—GSK3B—schizophrenia	2.64e-05	0.000147	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PDE4B—schizophrenia	2.63e-05	0.000146	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—ERBB3—schizophrenia	2.63e-05	0.000146	CbGpPWpGaD
Lithium—GSK3B—Signaling by WNT in cancer—EP300—schizophrenia	2.62e-05	0.000146	CbGpPWpGaD
Lithium—GSK3A—B Cell Activation—AKT1—schizophrenia	2.61e-05	0.000145	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CCKAR—schizophrenia	2.58e-05	0.000144	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—YWHAZ—schizophrenia	2.58e-05	0.000143	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MAG—schizophrenia	2.56e-05	0.000142	CbGpPWpGaD
Lithium—GSK3B—Disease—FGA—schizophrenia	2.53e-05	0.000141	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—ERBB3—schizophrenia	2.52e-05	0.00014	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—ADORA2A—schizophrenia	2.51e-05	0.000139	CbGpPWpGaD
Lithium—GSK3A—Immune System—S100B—schizophrenia	2.5e-05	0.000139	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—EP300—schizophrenia	2.5e-05	0.000139	CbGpPWpGaD
Lithium—GSK3B—Signaling by SCF-KIT—AKT1—schizophrenia	2.5e-05	0.000139	CbGpPWpGaD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—AKT1—schizophrenia	2.5e-05	0.000139	CbGpPWpGaD
Lithium—GSK3A—Disease—PRL—schizophrenia	2.48e-05	0.000138	CbGpPWpGaD
Lithium—GSK3B—BDNF signaling pathway—AKT1—schizophrenia	2.46e-05	0.000137	CbGpPWpGaD
Lithium—IMPA2—Metabolism—EP300—schizophrenia	2.43e-05	0.000135	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—FGA—schizophrenia	2.4e-05	0.000134	CbGpPWpGaD
Lithium—GSK3A—Immune System—ERBB4—schizophrenia	2.39e-05	0.000133	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling of activated FGFR—AKT1—schizophrenia	2.39e-05	0.000133	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB4—AKT1—schizophrenia	2.35e-05	0.000131	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CHRM1—schizophrenia	2.34e-05	0.00013	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—NPY—schizophrenia	2.34e-05	0.00013	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—ATP2A2—schizophrenia	2.34e-05	0.00013	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—NOTCH4—schizophrenia	2.34e-05	0.00013	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—IL3RA—schizophrenia	2.28e-05	0.000127	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—OXT—schizophrenia	2.26e-05	0.000126	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—HTR1B—schizophrenia	2.26e-05	0.000126	CbGpPWpGaD
Lithium—GSK3B—Insulin Signaling—AKT1—schizophrenia	2.26e-05	0.000125	CbGpPWpGaD
Lithium—GSK3B—Downstream signal transduction—AKT1—schizophrenia	2.25e-05	0.000125	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—AKT1—schizophrenia	2.24e-05	0.000124	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TLE1—schizophrenia	2.23e-05	0.000124	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NRG3—schizophrenia	2.23e-05	0.000124	CbGpPWpGaD
Lithium—GSK3B—Circadian rythm related genes—TP53—schizophrenia	2.23e-05	0.000124	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB2—AKT1—schizophrenia	2.22e-05	0.000124	CbGpPWpGaD
Lithium—GSK3B—Immune System—HLA-E—schizophrenia	2.22e-05	0.000123	CbGpPWpGaD
Lithium—GSK3B—Disease—SNAP25—schizophrenia	2.22e-05	0.000123	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—AKT1—schizophrenia	2.21e-05	0.000123	CbGpPWpGaD
Lithium—GSK3A—Disease—ERBB4—schizophrenia	2.21e-05	0.000123	CbGpPWpGaD
Lithium—GSK3A—Immune System—NRG1—schizophrenia	2.21e-05	0.000123	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—GFAP—schizophrenia	2.2e-05	0.000122	CbGpPWpGaD
Lithium—GSK3A—Immune System—MEF2C—schizophrenia	2.19e-05	0.000122	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—AKT1—schizophrenia	2.18e-05	0.000121	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—GRM5—schizophrenia	2.18e-05	0.000121	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—HTR1A—schizophrenia	2.17e-05	0.000121	CbGpPWpGaD
Lithium—IMPA1—Metabolism—EP300—schizophrenia	2.17e-05	0.00012	CbGpPWpGaD
Lithium—GSK3B—Signaling by Wnt—EP300—schizophrenia	2.16e-05	0.00012	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—NPS—schizophrenia	2.14e-05	0.000119	CbGpPWpGaD
Lithium—GSK3A—Immune System—YWHAZ—schizophrenia	2.12e-05	0.000118	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TLE3—schizophrenia	2.11e-05	0.000117	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—DRD1—schizophrenia	2.1e-05	0.000117	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—HTR2C—schizophrenia	2.1e-05	0.000117	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—AKT1—schizophrenia	2.08e-05	0.000116	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—AKT1—schizophrenia	2.08e-05	0.000116	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—AKT1—schizophrenia	2.08e-05	0.000116	CbGpPWpGaD
Lithium—GSK3A—Immune System—ERBB3—schizophrenia	2.07e-05	0.000115	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—AKT1—schizophrenia	2.06e-05	0.000115	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—AKT1—schizophrenia	2.05e-05	0.000114	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—NTRK2—schizophrenia	2.04e-05	0.000114	CbGpPWpGaD
Lithium—GSK3A—Disease—NRG1—schizophrenia	2.04e-05	0.000113	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—AKT1—schizophrenia	2.04e-05	0.000113	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—DRD3—schizophrenia	2.03e-05	0.000113	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—FOS—schizophrenia	2.02e-05	0.000112	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CCK—schizophrenia	1.99e-05	0.000111	CbGpPWpGaD
Lithium—GSK3B—Disease—HSPA1A—schizophrenia	1.99e-05	0.000111	CbGpPWpGaD
Lithium—GSK3B—Immune System—PRL—schizophrenia	1.98e-05	0.00011	CbGpPWpGaD
Lithium—GSK3B—Disease—NOS1—schizophrenia	1.97e-05	0.00011	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—DRD4—schizophrenia	1.97e-05	0.00011	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—AKT1—schizophrenia	1.97e-05	0.000109	CbGpPWpGaD
Lithium—GSK3A—Disease—YWHAZ—schizophrenia	1.95e-05	0.000109	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PDE4B—schizophrenia	1.94e-05	0.000108	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—AKT1—schizophrenia	1.93e-05	0.000107	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—AKT1—schizophrenia	1.92e-05	0.000107	CbGpPWpGaD
Lithium—GSK3A—Disease—ERBB3—schizophrenia	1.91e-05	0.000106	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CCKAR—schizophrenia	1.91e-05	0.000106	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CNR1—schizophrenia	1.89e-05	0.000105	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—ADORA2A—schizophrenia	1.85e-05	0.000103	CbGpPWpGaD
Lithium—GSK3B—Immune System—S100B—schizophrenia	1.85e-05	0.000103	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—AKT1—schizophrenia	1.84e-05	0.000103	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—DRD2—schizophrenia	1.84e-05	0.000102	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—HTR7—schizophrenia	1.84e-05	0.000102	CbGpPWpGaD
Lithium—GSK3A—Disease—MTHFR—schizophrenia	1.84e-05	0.000102	CbGpPWpGaD
Lithium—GSK3B—Disease—PRL—schizophrenia	1.83e-05	0.000102	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—EP300—schizophrenia	1.81e-05	0.000101	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—TP53—schizophrenia	1.79e-05	9.96e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—FGA—schizophrenia	1.78e-05	9.87e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—ERBB4—schizophrenia	1.77e-05	9.83e-05	CbGpPWpGaD
Lithium—GSK3B—TCF dependent signaling in response to WNT—AKT1—schizophrenia	1.76e-05	9.8e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PRL—schizophrenia	1.74e-05	9.65e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NPY—schizophrenia	1.73e-05	9.61e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NOTCH4—schizophrenia	1.73e-05	9.61e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—ATP2A2—schizophrenia	1.73e-05	9.61e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—APOE—schizophrenia	1.71e-05	9.5e-05	CbGpPWpGaD
Lithium—GSK3B—RNF mutants show enhanced WNT signaling and proliferation—AKT1—schizophrenia	1.71e-05	9.49e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—APOA1—schizophrenia	1.69e-05	9.4e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—HTR1B—schizophrenia	1.67e-05	9.28e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—OXT—schizophrenia	1.67e-05	9.28e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—ERBB4—schizophrenia	1.63e-05	9.08e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—NRG1—schizophrenia	1.63e-05	9.07e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—S100B—schizophrenia	1.62e-05	9e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—MEF2C—schizophrenia	1.62e-05	8.99e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—HTR1A—schizophrenia	1.61e-05	8.93e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—GSK3B—schizophrenia	1.6e-05	8.92e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—FOS—schizophrenia	1.59e-05	8.86e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling by WNT in cancer—AKT1—schizophrenia	1.59e-05	8.81e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NPS—schizophrenia	1.58e-05	8.79e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—YWHAZ—schizophrenia	1.56e-05	8.69e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—DRD1—schizophrenia	1.55e-05	8.62e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—HTR2C—schizophrenia	1.55e-05	8.62e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—ERBB4—schizophrenia	1.55e-05	8.6e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—ERBB3—schizophrenia	1.53e-05	8.5e-05	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—EP300—schizophrenia	1.52e-05	8.43e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NTRK2—schizophrenia	1.51e-05	8.39e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—NRG1—schizophrenia	1.51e-05	8.38e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—DRD3—schizophrenia	1.5e-05	8.35e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—GSK3B—schizophrenia	1.48e-05	8.23e-05	CbGpPWpGaD
Lithium—IMPA2—Metabolism—AKT1—schizophrenia	1.47e-05	8.17e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—DRD4—schizophrenia	1.46e-05	8.11e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PLA2G4A—schizophrenia	1.46e-05	8.09e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—YWHAZ—schizophrenia	1.44e-05	8.03e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—NRG1—schizophrenia	1.43e-05	7.94e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—AKT1—schizophrenia	1.42e-05	7.89e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MEF2C—schizophrenia	1.42e-05	7.87e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—ERBB3—schizophrenia	1.41e-05	7.85e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CNR1—schizophrenia	1.39e-05	7.74e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—YWHAZ—schizophrenia	1.37e-05	7.61e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—DRD2—schizophrenia	1.36e-05	7.55e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—HTR7—schizophrenia	1.36e-05	7.55e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—MTHFR—schizophrenia	1.36e-05	7.54e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—EP300—schizophrenia	1.34e-05	7.44e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—ERBB3—schizophrenia	1.34e-05	7.44e-05	CbGpPWpGaD
Lithium—IMPA1—Metabolism—AKT1—schizophrenia	1.31e-05	7.28e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling by Wnt—AKT1—schizophrenia	1.31e-05	7.26e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—HTR2A—schizophrenia	1.29e-05	7.16e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PRL—schizophrenia	1.28e-05	7.13e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—APOE—schizophrenia	1.26e-05	7.02e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—APOA1—schizophrenia	1.25e-05	6.94e-05	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—TNF—schizophrenia	1.23e-05	6.84e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—APOE—schizophrenia	1.2e-05	6.66e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—S100B—schizophrenia	1.2e-05	6.65e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—APOA1—schizophrenia	1.18e-05	6.58e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—IL1B—schizophrenia	1.18e-05	6.56e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—FOS—schizophrenia	1.18e-05	6.55e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—ERBB4—schizophrenia	1.14e-05	6.36e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—ESR1—schizophrenia	1.14e-05	6.35e-05	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—AKT1—schizophrenia	1.1e-05	6.09e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PLA2G4A—schizophrenia	1.08e-05	5.98e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NRG1—schizophrenia	1.06e-05	5.87e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—EP300—schizophrenia	1.06e-05	5.87e-05	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—AKT1—schizophrenia	1.05e-05	5.84e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MEF2C—schizophrenia	1.05e-05	5.81e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—GSK3B—schizophrenia	1.04e-05	5.76e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—YWHAZ—schizophrenia	1.01e-05	5.62e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—ERBB3—schizophrenia	9.89e-06	5.5e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—EP300—schizophrenia	9.74e-06	5.42e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—HTR2A—schizophrenia	9.52e-06	5.29e-05	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—AKT1—schizophrenia	9.16e-06	5.09e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—APOE—schizophrenia	8.85e-06	4.92e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—APOA1—schizophrenia	8.75e-06	4.86e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—IL1B—schizophrenia	8.72e-06	4.85e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—ESR1—schizophrenia	8.45e-06	4.7e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—AKT1—schizophrenia	8.09e-06	4.5e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—EP300—schizophrenia	7.8e-06	4.33e-05	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—AKT1—schizophrenia	7.77e-06	4.32e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—EP300—schizophrenia	7.2e-06	4e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—EP300—schizophrenia	6.82e-06	3.79e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—AKT1—schizophrenia	6.38e-06	3.55e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—AKT1—schizophrenia	5.89e-06	3.27e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—EP300—schizophrenia	5.04e-06	2.8e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TP53—schizophrenia	4.88e-06	2.71e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—AKT1—schizophrenia	4.71e-06	2.62e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—AKT1—schizophrenia	4.35e-06	2.42e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—AKT1—schizophrenia	4.12e-06	2.29e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TP53—schizophrenia	3.61e-06	2.01e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—AKT1—schizophrenia	3.05e-06	1.69e-05	CbGpPWpGaD
